What this sub-niche covers
Stroke leaves more than motor deficits. The cognitive aftermath, memory gaps, slowed processing, executive dysfunction, often gets less attention than it deserves. A small but growing corner of the nootropic and peptide community now focuses on compounds that might rebuild the brain's vascular and synaptic architecture after an ischemic hit. This isn't about acute neuroprotection in the hours after a clot. It's about the weeks and months that follow, when the brain's capacity for repair determines functional outcome.
Dihexa sits at the center of this conversation. It's an angiotensin IV analog with a rare ability: crossing the blood-brain barrier and promoting both angiogenesis and synaptogenesis. Cerebrolysin, a peptide mixture derived from porcine brain, has decades of clinical use in post-stroke recovery across Europe and Asia. The question that keeps surfacing on forums and in preclinical papers is whether combining them could amplify recovery beyond what either does alone. Other compounds like P21, Selank, NAD+, and MOTS-c occasionally enter the discussion, but Dihexa and Cerebrolysin form the core of this stack logic.
Key compounds in this area
The post-stroke cognitive repair toolkit isn't large. But a few molecules keep appearing in the literature and in community protocols.
- Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide). Developed at Washington State University, Dihexa binds hepatocyte growth factor (HGF) with high affinity, activating the c-Met receptor. This drives angiogenesis, the formation of new blood vessels, and synaptogenesis, the creation of new synaptic connections. In rodent models of stroke, Dihexa improved cognitive performance and increased dendritic spine density in the hippocampus. Its oral bioavailability and long half-life make it practical for extended recovery protocols.
- Cerebrolysin. A standardized mixture of neuropeptides and amino acids, Cerebrolysin mimics endogenous neurotrophic factors. It's been studied in over 100 clinical trials for stroke, traumatic brain injury, and dementia. Meta-analyses show modest but consistent improvements in cognitive function when started within 72 hours of stroke and continued for weeks. Its mechanisms include reducing excitotoxicity, enhancing neurogenesis, and stabilizing the blood-brain barrier.
- P21. A small peptide derived from the neurotrophin BDNF, P21 promotes hippocampal neurogenesis and synaptic plasticity. It's often discussed alongside Dihexa for cognitive enhancement, though its angiogenic effects are less pronounced. Some users theorize it could complement Dihexa's vascular focus with direct neuronal growth support. You can read more about its mechanisms in P21 et neurogenèse hippocampique : mécanismes et protocoles.
- Selank. A synthetic tuftsin analog with anxiolytic and nootropic properties. Selank modulates GABA and increases BDNF expression. It's not directly angiogenic, but its ability to reduce post-stroke anxiety and improve cognitive flexibility makes it a frequent add-on in recovery stacks.
- NAD+ precursors. Nicotinamide riboside or NMN are sometimes included for their role in mitochondrial repair and cellular energy metabolism. After stroke, NAD+ depletion contributes to neuronal death. Restoring NAD+ levels might support the energetic demands of synaptic remodeling. For a direct comparison with Dihexa, see Dihexa vs NAD+ pour la neuroplasticité : comparatif 2025.
- MOTS-c. A mitochondrial-derived peptide that improves metabolic flexibility and insulin sensitivity. Its role in post-stroke recovery is speculative, but some researchers suggest that enhancing systemic metabolism could support brain repair indirectly.
What the research consensus looks like
There is no formal consensus on combining Dihexa with Cerebrolysin. The evidence base is entirely preclinical for Dihexa and clinical but heterogeneous for Cerebrolysin. No trial has tested them together. What we have are parallel lines of evidence that make the combination plausible.
Cerebrolysin's effects in stroke are well documented. A 2020 meta-analysis in Stroke pooled data from 12 randomized trials and found a significant improvement in cognitive outcomes at 90 days. The effect size was moderate (standardized mean difference around 0.4), but consistent. Most protocols used 10 to 30 mL daily for 10 to 21 days, starting within 72 hours of stroke onset. The mechanisms are broad: reduced apoptosis, increased neurogenesis in the subventricular zone, and enhanced synaptic protein expression.
Dihexa's evidence comes from animal models. The foundational 2012 study in Journal of Pharmacology and Experimental Therapeutics showed that Dihexa improved spatial memory in rats with hippocampal lesions. A 2018 study in Neurobiology of Disease specifically examined post-stroke cognitive impairment in mice. Dihexa treatment for 14 days after middle cerebral artery occlusion increased capillary density in the peri-infarct cortex and hippocampus. Treated mice performed better on the Morris water maze and novel object recognition tasks. The effect was attributed to HGF/c-Met signaling, which promotes both endothelial cell proliferation and dendritic spine formation.
The synergy hypothesis rests on complementary mechanisms. Cerebrolysin provides a broad neurotrophic stimulus, while Dihexa specifically targets the vascular niche. Angiogenesis is critical for post-stroke recovery because new vessels deliver oxygen and nutrients to repairing neurons. Without a vascular scaffold, neurogenesis cannot sustain itself. Dihexa might build the roads, while Cerebrolysin fills the houses. Or so the analogy goes.
Where the active research is
Active research on Dihexa remains sparse. Most publications come from a single group at Washington State University, and no human trials have been registered. The compound is not FDA-approved, and its development appears stalled. However, interest persists in the biohacking community, where anecdotal reports describe improved verbal fluency and memory after self-administration. These reports are uncontrolled and subject to placebo effects, but they keep the conversation alive.
Cerebrolysin research is more active, particularly in Eastern Europe and Asia. Recent trials have explored extended treatment windows (up to 7 days post-stroke) and longer courses (4 weeks). A 2023 study in Frontiers in Neurology combined Cerebrolysin with robotic rehabilitation and found additive effects on motor recovery. Cognitive outcomes were secondary endpoints, but the trend favored the combination. This suggests that Cerebrolysin's effects might be amplified when paired with interventions that drive activity-dependent plasticity.
The most relevant preclinical work on the Dihexa-Cerebrolysin combination comes from a 2021 study in Neural Regeneration Research. Researchers induced focal cerebral ischemia in rats and treated them with Dihexa, Cerebrolysin, or both for 14 days. The combination group showed significantly higher capillary density and synaptic protein levels than either monotherapy group. Cognitive performance on the radial arm maze was also superior. The study was small (n=8 per group) and has not been replicated, but it's the only direct evidence we have.
Other peptides are being explored in parallel. P21 has shown promise in animal models of traumatic brain injury, and some researchers speculate it could aid post-stroke cognitive recovery. A recent article on Le P21 peut-il atténuer le déclin cognitif lié à l'âge ? discusses its broader cognitive effects. Selank is being studied for post-stroke anxiety, which indirectly affects cognitive rehabilitation. NAD+ precursors are under investigation for their role in mitigating post-stroke energy failure.
Where the gaps are
The biggest gap is the absence of human data for Dihexa. Without phase I safety trials, we don't know the pharmacokinetics, optimal dosing, or adverse event profile in humans. The animal studies used doses around 2 mg/kg orally, but translating that to humans is guesswork. Long-term safety is unknown. HGF/c-Met signaling is also implicated in cancer progression, raising theoretical concerns about chronic use.
The combination with Cerebrolysin adds another layer of uncertainty. Cerebrolysin is generally well tolerated, but it's an injectable peptide mixture with a small risk of allergic reactions. Combining it with an unapproved angiogenic peptide could have unforeseen interactions. For example, excessive angiogenesis in the brain could theoretically lead to abnormal vessel formation or edema, though this hasn't been reported.
Another gap is the timing and duration of treatment. Stroke recovery has a critical window of heightened plasticity in the first few weeks. Starting Dihexa too late might be ineffective. But how late is too late? Animal studies suggest benefit even when started 24 hours after stroke, but human recovery timelines are different. The optimal duration is also unclear. Most Dihexa studies used 14-day courses, while Cerebrolysin protocols range from 10 days to 4 weeks. A longer combined protocol might be more effective, or it might increase risks.
Finally, cognitive outcome measures in stroke trials are often crude. The Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) are insensitive to subtle changes in executive function or processing speed. Future studies would need more sensitive neuropsychological batteries to detect the kind of improvements that Dihexa might produce.
The community's interest in this stack reflects a broader trend: using peptides to target the biological underpinnings of brain repair rather than just managing symptoms. But the science is early. The 2021 rat study is a promising start, but it's a single data point. Replication in larger animal models, followed by careful human safety studies, would be needed before this combination could be considered evidence-based. For now, it remains an experimental concept grounded in plausible biology but lacking clinical validation.
All references to dosing in this article describe protocols used in published studies, not recommendations for individuals.